Metabolic profiling of vision loss

A panel of metabolites – small molecules that are part of metabolic processes – that are unique to macular degeneration will shed light on the disease and aid diagnosis.

Team tracking new options to treat glaucoma

Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain.

Grant to support blindess research

Research to Prevent Blindness (RPB) recently awarded a $110,000 grant to Vanderbilt’s Department of Ophthalmology and Visual Sciences in support of research into the causes, treatment and prevention of blinding diseases.

Vanderbilt ophthalmologist stresses summer eye safety

Insights on glaucoma gene mutations

Glaucoma-causing mutations in the gene for myocilin reduce secretion of the protein into the aqueous humor, suggesting a new option for treatment.

Blackburn presented ophthalmology Visionary Award